ViiV inches closer to making Celsentri available in India
This article was originally published in Scrip
Executive Summary
ViiV Healthcare, the specialist HIV joint venture established by GlaxoSmithKline and Pfizer, has zeroed in on a local partner to introduce its HIV entry inhibitor maraviroc (Selzentry/Celsentri) at an 'affordable' price in India.